INTRODUCTION
Purified polyclonal antibodies are invaluable tools for biochemical research 1 and for the production of antibody-derived biotherapeutics 2, 3 . Common techniques used for the purification of antibodies often involve affinity absorbents utilizing protein A derived from the cell wall of the microorganism S. aureus (widely used for the purification of monoclonal antibodies) 4 and protein G from Streptococcus as the affinity ligands 5 . However, the relatively high cost of these affinity absorbents for the purification of polyclonal antibodies 6, 7 combined with the additional cost of expensive cleaning solutions has resulted in the recent development of a number of commercial alternatives to protein A or G chromatography absorbents 8, 9 . Many of these chemical alternatives are applicable for the direct capture of antibodies from crude feedstocks.
Although recombinant protein A is a robust molecule that may be cleaned using relatively harsh cleaning conditions, the use of protein A or G for a primary capture step of antibodies directly from a feedstock such as serum may be problematic. This is due to the viscosity of the serum and the relatively high concentration of antibodies, other proteins (albumin, transferrin and other serum proteins) and non-protein impurities (lipids and often cryoprecipitates) that may remain nonspecifically adsorbed to the column and thus adversely impact the capacity and reuse of the column matrix. Such problems are often diminished when using absorbents with bound synthetic chemical ligands due to the chemical stability of the ligand and the opportunity to evaluate a combination of harsh cleaning protocols. This may help to ensure that nonspecifically adsorbed impurities are removed before subsequent chromatographic runs.
The MAbsorbent A2P ligand (Prometic BioSciences) is composed of a di-substituted phenolic derivative of trichlorotriazine and is commercially available coupled to a 6% crosslinked agarose (Purabead) chromatography bead ( Table 1) .
Here we present a detailed protocol for the direct capture and purification of polyclonal antibodies from ovine serum (see Table 2 for an overview of the purification steps). The purification protocol was developed after identifying critical parameters and optimizing process conditions using factorial experimental design 10 . Although similar protocols describing the purification of polyclonal antibodies from serum using alternative synthetic affinity absorbents have recently been described 11 , a major technical challenge to overcome when isolating antibodies from serum is the removal of nonspecifically bound serum proteins (particularly serum albumin) from the absorbent before IgG elution. The protocol described outlines the critical process steps, technical challenges and techniques to avoid potential purification issues that may arise when purifying polyclonal antibodies from clarified serum.
In our experience, the major limitation of the present method is the high back pressures that may be observed when purifying antibodies from serum using MAbsorbent A2P. This appears to be largely independent of serum viscosity and occurs during pH transitions. Increased back pressure may be due to absorbent compression resulting from ionization of the bound ligand affecting the rigidity of the agarose base matrix. This may in turn impact the performance of the absorbent for the purification of antibodies from serum using large-diameter commercial-scale chromatography columns 12 Although the protocol described herein has previously been evaluated for the purification of antibodies for the production of antibody-derived biotherapeutics 10 , this approach may be equally applicable for the purification of monoclonal antibodies for diagnostic or analytical techniques and may therefore be adapted for use in a wider range of applications. The protocol may also be applied for the purification of normal (non-hyperimmune) plasma antibodies and use with other chromatography absorbents utilizing small molecule ligands, such as hydrophobic charge induction chromatography 14, 15 . . Syringes (30 ml, BD Plastipak, BD, cat. no. 301229, or similar) . Ä KTA Explorer 100 (GE Healthcare, cat. no. 18-1112-41). A minimum of six buffer inlets are required for the protocol described. However, the method would be suitable for most commercially available laboratory-scale chromatography systems with minor modification to the method . Ä KTA detectors (GE Healthcare) used: UV-900 flow cell, 2 mm (cat. no. 18-1111-10), pH/C-900 pH and conductivity monitors (cat. no. 18-1107-76). An operational pressure limit of r0.7 MPa (101 psi, 7 bar) is recommended. This is determined from the combined operating pressure limit of the column (0.5 MPa) plus the back pressure observed from the flow restrictor included as part of the Ä KTA system (0. 2 MPa) . XK16/20 chromatography column (GE Healthcare, cat. no. 18-8773-01).
MATERIALS
m CRITICAL Low-pressure columns (C10 columns, GE Healthcare) may not be suitable for the protocol described owing to back pressure observed during pH transitions.
. Online Ä KTA filter kit (GE Healthcare, cat. no. 18-1027-11). m CRITICAL If filtered serum is loaded onto the column via the system pump, a new online filter should be installed or an apparent increase in back pressure will be observed. Alternatively, the in-line filter unit can be removed from the system before starting the method.
. The pH of the resulting solution should be checked using a pH meter after preparation. As the buffer has been formulated, pH adjustment is not required. However, minor adjustment with 1 M NaOH or concentrated HCl may be required if the final solution is not within this specification.
Wash buffer 25 mM sodium phosphate, 100 mM NaCl and 25 mM sodium octanoate pH 7.5 (±0.3). m CRITICAL Z25 mM sodium octanoate is required during column washing to remove residual albumin adsorbed to the chromatography matrix. The wash buffer is prepared by dissolving solids in the proportions described. The pH of the resulting solution should be checked using a pH meter after preparation. As the buffer has been formulated, pH adjustment is not required. However, minor adjustment with 1 M NaOH or concentrated HCl may be required if the final solution is not within this specification.
Elution buffer 50 mM sodium citrate pH 3.0 (±0.2). A formulated citrate buffer is prepared by dissolving the solids in the proportions described: the pH of the resulting solution should be checked using a pH meter after preparation. Subsequent pH adjustment is not required. 2| Connect the bottom end of an XK16 chromatography column to the Ä KTA system.
3| Gently agitate the absorbent, then slowly pour matrix into the column and permit settling of the matrix bed under gravity until a bed height of 22 cm is obtained.
4| Connect the top of the column and lower top adaptor to within 5 mm of the settled bed. 5| Pack the column using H 2 O at a flow rate of 13 ml min À1 . m CRITICAL STEP Owing to potential compression of this absorbent during polyclonal IgG elution, a high linear flow rate of 400 cm h À1 is recommended for packing. Pack the column using H 2 O for a minimum of 5 column volumes (CVs; final packed bed height of 20 cm ± 10%, 40 ml volume). 10| Start the fraction collector; collect 10 ml fractions. Elute bound antibodies from the column using elution buffer at 3.35 ml min À1 . m CRITICAL STEP During elution, many of the polyclonal antibodies transition through their isoelectric points and some haziness within concentrated fractions may be observed. Back pressure may be observed corresponding to an increased peak during IgG elution.
? TROUBLESHOOTING 11| Collect eluted fractions (approximately 60 ml) until baseline absorbance is observed (r0.05 AU). IgG fractions collected at the start of the elution peak may be hazy (see Step 10) . Once all eluted fractions are pooled, the final IgG solution will become clear. The final IgG concentration is 6-12 mg ml À1 (depending on serum IgG titer and elution volumes). A mass balance will confirm that all of the IgG has been eluted. Also trending column capacities and recoveries from subsequent runs will also indicate whether complete IgG elution has been observed. ? TROUBLESHOOTING Column cleaning and sanitization TIMING 1 h 12| Wash the column with 1 CV of low-pH cleaning buffer at 4.0 ml min À1 (120 cm h À1 ) and then continue to wash until the pH is o2.5 and the absorbance is less than 0.1 AU.
? TROUBLESHOOTING 13| Santize the column with 0.5 M NaOH at 2.0 ml min À1 for 40 min. m CRITICAL STEP Approximately 5-15% of polyclonal IgG remains adsorbed to the column. A low-pH wash and NaOH sanitization are required to remove adsorbed components. If the column is not cleaned sufficiently, then a drop in column capacity (and back pressure) may be observed when using the column for subsequent purification runs. An increase in pressure may be observed during pH transition into NaOH owing to the physical properties of the hydrophobic ligand and compression or swelling of the agarose base matrix. In this case, reduce flow rates for column sanitization.
? TROUBLESHOOTING Re-equilibration TIMING 0.5-1 h 14| Re-equilibrate the column with equilibration buffer at 2.0 ml min À1 until the pH is below 8.0.
15| If the column is not to be used for subsequent purification runs, flush the column with 5 CVs of H 2 O followed by Z3 CVs of matrix storage solution. The packed column may be detached, both ends capped and the column stored at 2-8 1C.
Alternatively, the matrix may be carefully rinsed as a slurry from the column (using storage solution) and stored at 2-8 1C in 20% ethanol (1:1 volume of ethanol to matrix).
pH adjustment of the IgG-containing solution TIMING 15 min 16| Adjust the pH of the purified IgG to neutral (pH 6-7) using 2 M Tris base or sodium hydroxide, syringe filter (0.2 mm) and store as required (at 2-8 1C for r3 days, at À20 1C for long term). Neutral pH adjustment of the eluted IgG and ZÀ20 1C storage is recommended to minimize aggregation, denaturation and degradation of the purified antibodies.
Analysis of antibody purity using Novex Tris-glycine gels TIMING 24-60 h 17| Prepare a 1Â Tris-glycine SDS running buffer solution by adding 100 ml of Novex Tris-glycine SDS running buffer (10Â) to 900 ml of H 2 O.
18| Remove a pre-cast Novex 4-20% Tris-glycine gel from the packet; remove the tape from the surface of the gel. Mark the position of the wells using a permanent marker. ! CAUTION Acrylamide is a possible human carcinogen and possible teratogen. Acrylamide is readily absorbed through the skin and may cause heritable genetic damage. Although polymerized polyacrylamide gels may present a reduced risk, ensure safety glasses and gloves are worn and handle in an area with adequate ventilation.
19| Place the gel into the Novex SureLock electrophoresis unit and fill the upper and lower buffer chambers with 600 ml of 1Â Tris-glycine SDS running buffer.
20| Gently remove the well comb and ensure the top of sample wells are filled and covered with running buffer.
21| Dilute the antibody solution to 1.0 mg ml À1 using H 2 O. Mix 10 ml (10 mg) with 10 ml of Tris-glycine SDS sample buffer in a 1.5 ml Eppendorf tube (final volume 20 ml) and immerse the samples in a boiling water bath for 2 min.
22|
Remove the samples and allow to cool for 3-5 min.
Centrifuge the samples for 5-10 s at room temperature at 16,000g within a benchtop centrifuge if condensation on the wall of the Eppendorf tube is observed.
23| Load 10 ml of sample per well (5.0 mg protein load) using gel loading pipette tips. Load also 10 ml of mark 12 molecular weight marker into one lane. 25| While the gel is running, pour approximately 50 ml of Coomassie Brilliant Blue R250 stain into a clean staining tray of appropriate size.
26|
After electrophoresis is complete, turn off the power, disconnect electrodes and remove the gel from the XCell SureLock Mini-Cell. Separate each of the three bonded sides of the cassette by inserting the gel knife into the gap between the cassette's two plates.
27|
Gently push down the knife to separate the plates. Repeat on each side of the gel cassette until the plates are completely separated. Carefully remove and discard the top plate, allowing the gel to remain on the bottom plate.
28| Use the sharp edge of the gel knife to remove the bottom lip of the gel. Hold the plate and gel over a container with the gel facing downward and use the knife to carefully loosen one lower corner of the gel and allow the gel to peel away from the plate into the suitable staining tray containing 50 ml of Coomassie stain prepared in Step 25.
29|
Stain the gel at room temperature with gentle agitation. After a minimum of 1 h, pour off the stain and destain the gel with 40% (v/v) methanol and 10% (v/v) glacial acetic acid until the background of the gel is clear upon visual inspection.
30| Destained gels may be scanned using a flatbed scanner and analyzed using densitometry analysis using ImageMaster TotalLab v2.01 image analysis software (or equivalent image capture and analysis software).
? TROUBLESHOOTING 31| Gels may be dried using the Invitrogen DryEase mini-gel drying system (Invitrogen instruction manual 052002, IM-2380) (Steps 17-22).
32| After staining and destaining steps are completed, wash the destained gel three times for 2 min each with H 2 O (50 ml per mini gel) on a rotary shaker. 33| Decant the water and add Gel-Dry drying solution (35 ml per mini gel). Equilibrate the gel in Gel-Dry solution for 15-20 min with gentle agitation.
34|
Remove two sheets of DryEase mini cellophane. Immerse one sheet in gel drying solution for 15-20 s. Place a DryEase gel drying frame on the DryEase gel drying base. Center a piece of pre-wetted cellophane over the base/frame combination so that the cellophane lays over the inner edge of the frame. Lay the gel on the center of the cellophane sheet ensuring no bubbles are trapped between the gel and the cellophane.
35|
Carefully lay a second pre-wetted cellophane sheet over the gel. Gently smooth out any bubbles and wrinkles in the assembly with a gloved hand.
36| Align the remaining frame so that the corner pins fit into the appropriate holes on the bottom frame. Push four plastic clamps onto the edges of the frames. Lift the frame assembly from the DryEase gel drying base and pour off any excess solution.
37| Stand the gel dryer assembly upright. ' PAUSE POINT Dry at room temperature for 12-36 h. ? TROUBLESHOOTING 38| When the cellophane is dry to the touch, remove the gel/cellophane sandwich and trim the edges. Press the dried gel between the pages of a notebook for 2 days. Gels will remain flat for scanning or photography.
TIMING
Steps 1-7, serum filtration and column preparation and packing: 1-2 h Steps 8-11, antibody purification: 3 h Steps 12 and 13, column cleaning and sanitization: 1 h
Step 14, column re-equilibration: 0.5-1 h
Step 15, matrix storage: 1.5-2 h
Step 16, pH adjustment of purified antibodies: 15 min Steps 17-38, analysis of IgG purity by SDS-PAGE: 24-60 h (time will be dependent on whether gels are destained overnight and whether gels are dried before densitometry analysis)
? TROUBLESHOOTING Troubleshooting advice can be found in Table 3 . A consistent color will return after re-equilibration into neutral pH buffer. Column performance will not be affected
ANTICIPATED RESULTS
Typical isolated yields of purified polyclonal IgG will be B80%, although this may be dependent on polyclonal IgG titers within the serum. Although an approximate IgG serum titer of 30 mg ml À1 has been presented, an accurate serum IgG titer may be determined using protein G chromatography or an alternative analytical technique 16 . A representative chromatogram with absorbance (280 nm), pH and conductivity traces is shown in Figure 1 . IgG purities (as determined by Coomassie-stained SDS-PAGE and scanning densitometry) 10 will be 90% (Fig. 2) . Step Problem Possible reasons Solution
